Renaissance Technologies (RenTech)'s ENGN Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 156,100 shares of enGene Therapeutics Inc. (ENGN) worth $1.06 M, representing 0.00% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 4 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in ENGN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 135,318 shares. Largest reduction occurred in Q3 2025, reducing 11,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s enGene Therapeutics (ENGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly enGene Therapeutics (ENGN) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +135,318 | Add 651.13% | 156,100 | $6.81 |
| Q4 2025 | +20,782 | New Buy | 20,782 | $9.03 |
| Q3 2025 | -11,400 | Sold Out | 0 | $0.00 |
| Q2 2025 | +11,400 | New Buy | 11,400 | $3.64 |
Renaissance Technologies (RenTech)'s enGene Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased enGene Therapeutics Inc. (ENGN) in Q2 2025, acquiring 11,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held enGene Therapeutics Inc. (ENGN) for 4 quarters since Q2 2025.
Renaissance Technologies (RenTech)'s largest addition to enGene Therapeutics Inc. (ENGN) was in Q1 2026, adding 156,100 shares worth $1.06 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 156,100 shares of enGene Therapeutics Inc. (ENGN), valued at approximately $1.06 M.
As of the Q1 2026 filing, enGene Therapeutics Inc. (ENGN) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in enGene Therapeutics Inc. (ENGN) was 156,100 shares, as reported at the end of Q1 2026.